


PHARMACEUTICAL 2021



AGILE THERAPEUTICS INC Rank 309 of 409





PHARMACEUTICAL 2021



AGILE THERAPEUTICS INC Rank 309 of 409

The relative strengths and weaknesses of AGILE THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGILE THERAPEUTICS INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 74% points. The greatest weakness of AGILE THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 183% points.

The company's Economic Capital Ratio, given in the ranking table, is -323%, being 32% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	56,785
Cost of Goods Sold	282
Intangible Assets	0
Liabilities, Current	7,353
Liabilities, Non-Current	0
Other Assets	2,034
Other Compr. Net Income	3.0
Other Expenses	23,285
Other Liabilities	16,381
Other Net Income	-2,800
Property and Equipment	14,243
Research and Development	13,500
Revenues	749
Selling, General and Administrative Expense	12,735

Output Variable	Value in 1000 USD
Assets	73,062
Liabilities	23,734
Expenses	49,802
Stockholders Equity	49,328
Net Income	-51,853
Comprehensive Net Income	-51,852
Economic Capital Ratio	-323%